Conatus Presents Data Demonstrating Emricasan's Safety Profile at AASLD Liver Meeting
Conatus Pharmaceuticals (Nasdaq: CNAT) today announced that data from the Phase 1 clinical trial of emricasan, a first-in class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, are being presented at The Liver Meeting®, the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) on November 4, 2013 in Washington, D.C. The Phase 1 clinical trial was conducted to understand the activity of emricasan on caspase activity in healthy subjects.
Emricasan is a potent inhibitor of pro-apoptotic and pro-inflammatory caspases, and in prior Phase 1 and Phase 2 clinical trials, has been shown to rapidly suppress apoptotic caspase activity as determined by a key biomarker of inflammation and cell death, caspase cleaved CK18 (cCK18), in hepatitis C virus (HCV) patients to within ranges typically reported for healthy volunteers. Caspase activity is